Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Pfizer Japan Aims to Boost MR Productivity by 50% in 5 Years: Mr Bootes
March 22, 2004
- Draft GL for Drug Testing Organizations Presented
March 15, 2004
- REGULATORY NEWS IN BRIEF
March 15, 2004
- Korosho to Promote Prevention of the Need for Nursing Care
March 15, 2004
- Generic Drug Use Increasing Steadily at Pref. Hospitals: PJ Survey
March 15, 2004
- Pfizer Working to Boost Motivation, Research Efficiency
March 15, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 15, 2004
- Takeda to Remain No. 1 in Priority Fields under New Marketing System: Mr Yamaoka
March 15, 2004
- Japanese Healthcare Q&A (6)
March 15, 2004
- Yamanouchi to Promote Stasis in Patients with Mild Diabetes
March 15, 2004
- Fujisawa's R&D Pipeline Updated
March 15, 2004
- Banyu to Focus More Resources on Marketing of Fosamac
March 15, 2004
- New GL for Cerebral Apoplexy Released
March 15, 2004
- Teijin Pharma to Expand MR Force to Boost Sales of Bonalon
March 15, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 15, 2004
- Sumitomo: FY2003 Sales to Fall Short of Forecast, but Profits Go as Expected
March 15, 2004
- DIAGNOSTIC NEWS IN BRIEF
March 15, 2004
- Eisai Formally Decides to Adopt "Company with Committees" System
March 15, 2004
- OTC NEWS IN BRIEF
March 15, 2004
- Symposium Discusses Use of Bar Codes to Prevent Medication Errors
March 15, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…